Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Saturday, July 28, 2012

Link found between Vitamin D and MS drug


July 27, 2012
MARK COLVIN: Scientists at the Menzies Research Institute in Hobart have made an important discovery about one of the most common drug used to treat MS. 

They've found that the drug - interferon-beta- appears to boost people's ability to absorb vitamin D from sunlight. 

In a study of 178 Tasmanians with MS the scientists found that patients on the drug were able to absorb three times as much vitamin D from the sun as those not on the drug. 

Felicity Ogilvie reports from Hobart. 

FELICITY OGILVIE: Multiple Sclerosis or MS is a disease that attacks the central nervous system. 

It's been three years since the 30-year-old mother of two, Jayne England, found out that she has MS. 

JAYNE ENGLAND: Within a week I basically went numb down the left side of my body and I went to the doctor's and I went and had CTs and MRIs and was diagnosed within two days. So it was a really quick diagnosis. 

FELICITY OGILVIE: One of the medications that Mrs England was given to treat her MS was Interferon-beta. The drug is given to patients via injection. 

And scientists at the Menzies Research Institute in Hobart have recently discovered there's a link between the drug and vitamin D. 


Continue reading


..
 Please note that all comments are moderated. 

 So that you can be kept up to date with MS information
Become a Member of MS Views and News
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Wednesday, July 25, 2012

ONE Drug For Alzheimer's, Parkinson's And MS Shows Promise


July 25, 2012
A "one-size-fits-all" new class of drugs that targets a particular type of brain inflammation is showing early promise for the treatment of Alzheimer's disease, Parkinson's disease, multiple sclerosis and traumatic brain injury. 

A pre-clinical study due to be published this week in the Journal of Neuroscience shows one of the drugs stopped mice bred to have Alzheimer's from developing the full-blown disease.

The new class of drugs, developed at Northwestern University Feinberg School of Medicine in the US, approaches the treatment of Alzheimer's differently to the ones currently being tested to prevent beta amyloid plaques in the brain. While the plaques are known to indicate Alzheimer's, nobody has yet proved that they cause the disease.

A press statement released on Tuesday reveals Northwestern has already been issued with patents to cover the drugs and has licensed commercial development to a biotech company that has just completed the first phase 1 clinical trial which tests safety in humans.

The new class of drugs, currently known as MW151 and MW189, target a particular type of brain inflammation that is a common denominator in MS, Alzheimer's and Parkinsons, and also in traumatic brain injury and stroke.

More and more scientists are coming round to the idea that inflammation plays a major role in the progressive damage that characterizes these chronic neurological diseases and brain injuries.


Continue Reading


..
 Please note that all comments are moderated. 

 So that you can be kept up to date with MS information
Become a Member of MS Views and News
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

MSVN now partners with Shop.com



Dear Friends;

We are pleased to announce our new, exciting partnership with Shop.com. Shop.com/msvn has infinite potential as a fundraising vehicle. Just shop and save, and shop and earn cash donations to MS Views and News.

MS Views and News now has our own shopping portal, www.shop.com/msvn, which provides an amazing yet easy shopping experience by offering Comparative Shopping, One Stop Shopping Cart, Hot Deals with coupons and more. 


 In addition to all of your purchases supporting MS Views & News, you will earn 2%-50% CASH BACK on all your purchases.  Plus, when you refer your friends and family to our portal, you will earn ½% CASH BACK on all of their purchases.  They also will receive CASH BACK for shopping and MS Views and News will earn royalties on all purchases.  It’s a win-win situation for everyone! 

Through www.shop.com/msvn, you can access over 3,500 brand name partner stores which include Target, Wal-Mart, Macy’s, Toys R Us, Gap, Sears, Apple, Bloomingdales, Saks, Best Buy and more!  Market America, an online brokerage company, also offers over 2,500 of their branded products such as Health & Nutrition, Weight Management, Anti-Aging, Personal Care, Cosmetics, Home & Garden, Auto  Care, Pet Care, Telecommunications, Financial Services and Website Development.

There’s just too much to tell about in one email so pop over to our site right now by going to www.shop.com/msvn and click sign in.  There you can register for free! This new venture is our way of saying Thanks for your continued support.

Happy Shopping!

Thank You,

The MS Views and News/Stu's View & MS News  TEAM


..
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Entertainment Video: What a Wonderful World


Entertaining Video:



                                               Click, relax and Enjoy


 "LIKE" our Blog - Click the link found upper left - thank you

..
 Please note that all comments are moderated. 

 So that you can be kept up to date with MS information
Become a Member of MS Views and News
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Autoimmune Diseases and the potential role of Chinese Herbal Medicine


Information provided by: Annie Gordon, A.P, M.S.TCM

BACKGROUND TO THE DISEASE CATEGORY

Autoimmune diseases are chronic disorders that have been difficult, and often impossible, to cure.  There can be remission of symptoms—spontaneously or as the result of applied therapies—but the potential for return of the disease remains in almost all cases.  The characteristic of these diseases is immune system targeting of body components, so that these components are damaged, either temporarily or permanently, or their activities are altered.  The autoimmune diseases almost always have a significant genetic component; in addition many of the diseases in this category appear to have a viral or other infectious agent as a trigger for onset of the autoimmune status.  There may be a variety of other factors that are important to finally set off a pattern of symptomatic disease so that its first manifestation may be after age 20 (there are also late-onset autoimmune diseases).  In fact, if the disease appears much earlier than that (i.e., prior to the teen years), it is usually a very aggressive form with a strong genetic component. 
There are dozens of diseases that are classified as involving autoimmune responses or suspected of having an autoimmune basis.  In many of the diseases, there is a significant difference in incidence among men and women; overall, women are about 3 times as likely as men to suffer from autoimmune disorders (however, in some disorders, such as MS, men appear to have a more severe disease pattern).  If the initial symptoms are mild or if the disease progresses slowly or develops its symptoms in an unusual pattern, diagnosis is difficult.  Some patients relay experiences of pursuing medical diagnosis and treatment for a decade before getting a definitive disease name.  A greater number of tests that can suggest or confirm presence of an autoimmune disease have become available so that it is now easier to make a diagnosis than ever before, but some disorders suspected of being autoimmune diseases still lack reliable tests, especially for their early stages.
The incidence of autoimmune diseases in the U.S. has been estimated to be just over 3%, with a current affected population of about 10 million people.  Societies representing people suffering from autoimmune diseases consistently over-report the incidence rates, using the upper limits from the highest estimate ranges; thus, the incidence rates given in these circumstances—often relayed by the news media—must be interpreted cautiously.  Some of the common autoimmune disorders are outlined below.
Connective Tissue Diseases
The most prevalent autoimmune disorders are connective tissue diseases, accounting for nearly half of all the cases; rheumatoid arthritis is the dominant one.  
The main connective tissue diseases are:   CLICK HERE to CONTINUE


..
 Please note that all comments are moderated. 

 So that you can be kept up to date with MS information
Become a Member of MS Views and News
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Topic: MS Patient Videos and MS Patient Stories


MS Views and News is getting ready to launch a new website.

On this new and informative site, we will have a new section for patient videos and patient stories.
We invite you to provide us with videos or stories that you may want to share with the world.

Additionally, we also want to begin an area for the caregiver(s). You too can submit your own stories about being a Caregiver/caregiving and you too can submit a video from your perspective.

Because of the amount of information we expect to be receiving, we may not be able to post all videos and not all stories. Please keep to a 'PG' or 'G' rating.

Additionally, if anybody has or can find a professionally made video about having anything to do with Multiple Sclerosis and especially if this video is obtained from YouTube, please send us the link for this as we will have a featured video on our home page such as the one shown here.

Providing us with the above, will help us to provide for others who might benefit from the information.

To submit, please send to info@msviewsandnews.org

Best Regards,

The MS Views and News / Stu's Views & MS News TEAM


..
 Please note that all comments are moderated. 

 So that you can be kept up to date with MS information
Become a Member of MS Views and News
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Acorda Therapeutics Statement on AMPYRA® (dalfampridine) Annual Drug Safety Communication



ARDSLEY, N.Y. – July 25, 2012 – As part of a planned annual safety review, the U.S. Food and Drug Administration (FDA) has issued a safety update on AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. AMPYRA is being developed and marketed by Acorda Therapeutics, Inc. (Nasdaq: ACOR).
The Company’s Risk Evaluation Mitigation Strategy (REMS) for AMPYRA includes a commitment to provide annual post-marketing experience data to the FDA. The information in the annual FDA drug safety communication is based on data reported from March 2010 through March 2011.
These data showed no new safety signals related to seizure risk with AMPYRA, and are consistent with the data from clinical trials of AMPYRA.
This FDA communication clarifies prescribing information and continues to recommend that physicians monitor kidney function and for seizure activity. It also informs physicians and patients that the majority of seizures happened within days to weeks after starting the recommended dose and in patients having no history of seizures.
From March 2010 through March 2011, approximately 46,000 people with multiple sclerosis (MS) filled at least one prescription for AMPYRA. Among those patients, there were 82 confirmed reports of seizure. This rate is consistent with that seen in AMPYRA clinical trials. 
AMPYRA is contraindicated in patients with moderate or severe renal impairment, and the FDA continues to recommend that kidney function be checked in patients before starting AMPYRA. The FDA additionally recommends physicians evaluate kidney function at least once a year for patients taking AMPYRA, as calculated from a routine blood test.
The Company does not expect any changes to the REMS program or post-marketing commitments as a result of this update.
Important Safety Information
AMPYRA can cause seizures; the risk of seizures increases with increasing AMPYRA doses. AMPYRA is contraindicated in patients with a prior history of seizure. Discontinue AMPYRA use if seizure occurs.


..
 Please note that all comments are moderated. 

 So that you can be kept up to date with MS information
Become a Member of MS Views and News
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Ampyra (dalfampridine): Drug Safety Communication - Seizure Risk for Multiple Sclerosis Patients



July 24, 2012 - FDA is updating health care professionals and the public about the risk of seizures in patients with multiplesclerosis (MS) who are starting Ampyra(dalfampridine). Using information received from post-market adverse event reports, FDA recently evaluated seizure risk in MS patients taking Ampyra (dalfampridine).  The majority of seizures happened within days to weeks after starting the recommended dose and occurred in patients having no history of seizures. The FDA is updating the Ampyra drug label to clarify recommendations.
BACKGROUND: Ampyra was approved to improve walking in patients with MS. Seizures are a known side effect of Ampyra, and seizure risk increases with higher blood levels of the drug.  Ampyra is eliminated from the body through the kidneys, and patients with kidney impairment may develop higher blood levels of the drug, thereby increasing their seizure risk. 
RECOMMENDATION: FDA reminds health care professionals that there are age-related decreases in renal function, and mild renal impairment is common after age 50, even when serum creatinine is normal.  Renal function should be assessed by estimating creatinine clearance. Ampyra should not be used in patients with a history of seizures or who have moderate to severe renal (kidney) impairment (measured as creatinine clearance [CrCl] less than or equal to 50 mL/min).
Additional information for Patients includes:
  • Tell your health care professional if you have kidney problems.
  • Your health care professional should order blood tests periodically to evaluate your kidney function.
  • Do not take Ampyra if you have ever had a seizure.
  • Ampyra tablets should be taken whole and not divided, crushed, chewed, or dissolved.
  • Do not take double or extra doses of Ampyra if a dose is missed.  Side effects, including seizures, are more frequent at higher doses.
Additional information for Health Care Professionals includes:
CLICK HERE to continue reading


..
 Please note that all comments are moderated. 

 So that you can be kept up to date with MS information
Become a Member of MS Views and News
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Monday, July 23, 2012

Stu's Views on Diets and Nutrition for MS


Published on Jul 19, 2012 by MSViewsandNews



Stu's Views on: 'the all too many diets', that are being broadcast as being good "for" Multiple Sclerosis, with so many claiming that what they do, is the correct "one" to be doing. This podcast is truly Stuart's opinion.

 For professional advice, speak with a healthcare professional




~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
..
 Please note that all comments are moderated. 

 So that you can be kept up to date with MS information
Become a Member of MS Views and News

Neil Riordan PhD - HIS VIEWPOINT on Stem Cell Therapy for Stem Cell Treatments



Published on Jul 23, 2012 by 

Dr. Riordan discusses current US FDA oversight of adult stem cell treatments, "practice of medicine" treatments that are neither regulated nor approved by the FDA, historical examples of successful medical procedures such as bariatric surgery, liposuction and ulcer treatments which were violently opposed by researchers, physicians and companies with competing financial interests.






..
 Please note that all comments are moderated. 

 So that you can be kept up to date with MS information
Become a Member of MS Views and News
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Information on BG-12 from an MS Peers' blog




BG-12
BG-12 (BG00012, Dimethyl Fumarate) is an investigational oral therapy in Phase III clinical development as a monotherapy for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS), in Phase II clinical development for Rheumatoid Arthritis (RA). 

BG-12 received Fast Track designation in MS from the U.S. Food and Drug Administration (FDA), which may expedite U.S. regulatory review. Biogen Idec retains full worldwide commercial rights to BG-12. 

Both U.S. and European regulators have accepted for review Biogen Idec's application for experimental Multiple Sclerosis drug BG-12, the company said on Wednesday.

The pill is seen by some Wall Street analysis as having the potential to become the world's leading treatment for the chronic, disabling disease that attacks the central nervous system and can lead to numbness, paralysis and loss of vision.

Biogen already makes the Multiple Sclerosis 
drugs Avonex and Tysabri, which are given by injection.

The company said the U.S. Food and Drug Administration granted a standard 10-month review for BG-12 and the European regulatory agency has validated its application. Both applications were submitted in the first quarter of 2012. We'll keep our eyes peeled out for it, and update you with our thoughts on it as more info. is released.



Source: Suddenly MS




..
 Please note that all comments are moderated. 

 So that you can be kept up to date with MS information
Become a Member of MS Views and News
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Sea anemones venom key to Multiple Sclerosis treatment



The purple sea anemone awaits passing prey, which it stings with its venom-filled tentacles
A beautifully colored purple sea anemone awaits passing prey, which it stings with its venom-filled tentacles
Sea anemones use venomous stinging tentacles to stun their prey, but one component of that venom is being used by researchers to treat the debilitating effects ofMultiple Sclerosis (MS).

A new class of drugtreatment is about to commence clinical trials, as the result of a decade-long investigation byProfessor Ray Norton, from the Monash Institute of Pharmaceutical Sciences and his collaborators, who in the mid 1990s found a component of venom called ShK in the Caribbean sea anemone.

The researchers found ShK blocks the Kv1.3 potassium channel located in white blood cells, known as T-cells, which are known to produce nerve damage in MS, one of the most common and debilitating diseases of the nervous system.

Professor Norton has since collaborated with a team of scientists in the United States investigating potassium channels as targets for the development of novel immunosuppressive agents.

With potassium channels controlling all sorts of key functions in the human body, developing a drug without unwanted side effects would have been impossible had it not turned out that the Kv1.3 potassium channel is found only on T-cells and in the nose. Because of this limited distribution, the researchers were able to develop a highly selective immune suppressant derived from the sea anemone peptide.

Professor Norton said that by blocking the potassium channels, ShK prevented the T-cells from attacking the nervous system and causing the paralysis observed in MS patients.

"This research shows that we may be able to effectively treat the disease while protecting the immune system," Professor Norton said.

“Continuously blocking these T-cell channels with ShK should prevent further nerve damage, even after the initial onset of symptoms, including paralysis. If the clinical trials are successful, this could prove an effective treatment for MS.”

Professor Norton said ShK is one of the most potent inhibitors known for these channels.

“The next step is to find out what dose works best to treat MS and at what stage of the diseasetreatment should begin," Professor Norton said.

A close relative of corals and jellyfish, sea anemones spend most of their time attached to rocks on the sea floor or on coral reefs waiting for crustaceans and small fish to pass close enough to get entangled in their venom-filled tentacles.
Monash University.

Source: HEALTHCANAL



..
 Please note that all comments are moderated. 

 So that you can be kept up to date with MS information
Become a Member of MS Views and News
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Sunday, July 22, 2012

August 18th in Ft. Myers, Fl. - MS Treatment Strategies & Therapeutic Symptom Management




                                Register for this program by sending 
                             an RSVP to: stuart@msviewsandnews.org


~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

MS Symptom Management and IMPACT of MS on the Family - an MS Seminar for Aug 7th In Miramar, Florida





                                      RSVP to: info@msviewsandnews.org 





Heat & Temperature Sensitivity concerning those with Multiple Sclerosis



Click HERE to read this article which was posted originally in 2009 but is still worthy to be re-posted each year  


..
 Please note that all comments are moderated. 

 So that you can be kept up to date with MS information
Become a Member of MS Views and News
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~